Table 1.
Descriptive statistics of participants, by study sites
| Characteristics | Htoo Pyin Nyar | Tar Au Ta | Ka Nu Hta | Htee Kaw Taw | ||||
|---|---|---|---|---|---|---|---|---|
| Age (years), median (range) | 21 (0–66) | 19 (0–80) | 22 (0–73) | 19 (0–94) | ||||
| Female gender, % | 47 | 52 | 46 | 50 | ||||
| Pf prevalence by uPCR % (no. positive/no. tested) | 0.88 (17/1,934) | 2.77 (51/1,843) | 3.14 (64/2,036) | 1.62 (59/3,648) | ||||
| Pf incidence by rapid diagnostic test (cases per 1,000 per year) | 11.4 | 45.5 | 6.6 | 1.0 | ||||
| Antibody prevalence to gSG6-P1 | 59.3 (1,131/1,906) | 68.8 (1,356/1,970) | 61.4 (1,256/2,046) | 86.3 (3,024/3,503) | ||||
| Antibody prevalence to Pf antigen, visits (%) | CSP | MSP-119 | CSP | MSP-119 | CSP | MSP-119 | CSP | MSP-119 |
| All ages | 6.0 (113/1,892) | 66.7 (1,268/1,902) | 14.5 (284/1,958) | 73.7 (1,452/1,969) | 8.7 (179/2,050) | 77.9 (1,591/2,043) | 6.7 (231/3,469) | 61.3 (2,136/3,484) |
| Ages 0–4 years | 0.4 (1/241) | 51.4 (125/243) | 3.2 (10/309) | 28.0 (87/311) | 1.3 (3/225) | 44.0 (99/225) | 1.5 (7/453) | 23.9 (109/456) |
| Ages 5–15 years | 3.6 (20/551) | 63.6 (353/555) | 5.4 (34/627) | 66.4 (420/633) | 4.1 (22/540) | 68.8 (368/535) | 3.4 (431/1,262) | 54.0 (683/1,264) |
| Ages 16–59 years | 8.7 (91/1,051) | 70.9 (748/1,055) | 21.7 (202/932) | 91.8 (857/934) | 11.9 (145/1,215) | 86.9 (1,055/1,214) | 9.9 (165/1,661) | 76.2 (1,273/1,671) |
| Ages > 60 years | 2.0 (1/49) | 85.7 (42/49) | 42.2 (38/90) | 96.7 (88/91) | 12.9 (9/70) | 100.0 (69/69) | 17.2 (16/93) | 76.3 (71/93) |
MSP-119 = merozoite surface protein 119; uPCR = ultrasensitive qPCR.